Appliation of compound mylabris capsules combined with concurrent chemoradiotherapy in cervical carcinoma
10.3760/cma.j.issn.1673-422X.2016.11.006
- VernacularTitle:复方斑蝥胶囊联合同步放化疗在宫颈癌中的应用
- Author:
Yunyan TAI
;
Dongfeng PAN
;
Fengjun CAO
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Radiotherapy;
Chemotherapy,adjuvant;
Drug therapy
- From:
Journal of International Oncology
2016;43(11):826-828
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and adverse reactions of compound mylabris capsules combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer. Methods From September 201 3 to September 201 4,we collected 80 patients with stage ⅡB-ⅣA cervical cancer who were admitted to Cancer Center of Affiliated People′s Hospital of Hubei University of Medicine. They were divided into the observation group (n =40)and control group (n =40)according to random number table.Patients of observation group were treated with compound mylabris capsules combined with chemo-radiotherapy,and patients of the control group were treated with the concurrent chemoradiotherapy alone.TP scheme of paclitaxel plus cisplatin was used in chemotherapy.Intensity-modulated radiation therapy (IMRT) and intracavitary brachytherapy was used in radiotherapy.The effective rates,Karnofsky Performance Status (KPS)scores,and recent adverse reactions in the two groups were compared.Results The short-time effec-tive rates in the observation group and control group were 97.5% and 95.0% respectively,with no significant difference (χ2 =0.346,P =0.556).The grade Ⅲ-Ⅳ adverse reactions in the observation group and control group included leucopenia (80.0% vs.95.0%),lower hemoglobin (22.5% vs.45.0%),thrombocytopenia (60.0% vs.82.5%),radioactive urocystitis (5.0% vs.30.0%),radioactive proctitis (1 0.0% vs. 30.0%),with significant differences (χ2 =4.1 1 4,P =0.043;χ2 =4.528,P =0.033;χ2 =4.943,P =0.026;χ2 =8.658,P =0.003;χ2 =5.000,P =0.025).The KPS score in the observation group was higher than that in the control group (90 vs.70),with significant difference (Z =4.523,P =0.000).Conclusion The clinical efficacy of compound mylabris capsules combined with concurrent chemoradiotherapy and chemoradio-therapy alone for patients with locally advanced cervical cancer are similar.Compound mylabris capsules can re-duce the rates of adverse reactions such as leucopenia,lower hemoglobin,thrombocytopenia,radioactive urocysti-tis and radioactive proctitis,and can improve KPS score,which plays a role of reliving toxicity.
